Core Viewpoint - The company has approved a licensing and commercialization agreement for BAT2206, receiving a milestone payment of $2.5 million from Jireh Pharmaceuticals, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The company received a one-time milestone payment of $2.5 million, which strengthens its cash reserves [1] - The payment is expected to assist in the advancement of the company's pipeline research and international strategy [1] Group 2: Product Development - BAT2206 injection has been approved for market by the U.S. FDA and the European Medicines Agency, with the U.S. brand name STARJEMZA® and the European brand name Usymro® [1] - The company has submitted a marketing application to the National Medical Products Administration, which is currently under review [1]

Core Viewpoint - The company received a milestone payment of $10 million from Hikma, which enhances its cash reserves and supports future pipeline development and international strategy [1] Group 1: Financial Impact - The $10 million payment will be credited after deducting bank fees, contributing positively to the company's financial position [1] Group 2: Product Development - The company's product BAT2206 (Ustinumab injection) has received approvals from both the FDA and EMA, with the U.S. brand name being STARJEMZA® and the European brand name Usymro® [1] - A marketing application for BAT2206 has been submitted to the National Medical Products Administration (NMPA) and is currently under review [1]

Core Viewpoint - Baotai Biopharmaceutical Co., Ltd. has received approval from the European Commission for Usymro®, a biosimilar drug for treating moderate to severe plaque psoriasis, active psoriatic arthritis, and moderate to severe active Crohn's disease in adults and children, marking a significant milestone for the company [2][3] Company Overview - Baotai is a global biopharmaceutical company based in Guangzhou, China, focused on developing innovative drugs and biosimilars for various diseases, including cancer and autoimmune disorders [2][3] - The company has successfully launched multiple drugs, including Adalimumab and Tocilizumab, in various markets, establishing itself as a leader in antibody drug development [3] Recent Developments - The approval of Usymro® follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in June 2025, highlighting the company's commitment to advancing its biosimilar pipeline [2] - In October 2024, Baotai signed a licensing and commercialization agreement with Gilead Sciences for BAT2206, another biosimilar, covering markets in the EU, UK, Switzerland, and other regions [2]